A Phase 1b/2 Randomized Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Brief description of study

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine to participants with colorectal cancer.


Clinical Study Identifier: s22-01548
ClinicalTrials.gov Identifier: NCT05609370
Principal Investigator: Kristen Spencer.
Other Investigators: Laura Palazzolo, Paul E. Oberstein, Daniel J Becker, Anam Qureshi, Marta Wioleta Wronska, Carol M Lee, Michael Shusterman, Jonathan B Kahn, Monica Rivera, Keriann M Scavone, Nitish Mehta, Nina Beri, Jennifer Chuy, Anastasiya Apanasyuk, Rafael Winograd, Shun Yu, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.